Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On May 30, 2019, the PMPRB published the 2018 edition of the Meds Pipeline Monitor, a horizon scanning report which provides a snapshot of the new drug landscape
On May 30, 2019, the PMPRB published the 2018 edition of the
Meds Pipeline Monitor, a horizon scanning report which
provides a snapshot of the new drug landscape (see
news release). The report considered the 733 medicines
currently in Phase III clinical trials or pre-registration with the
US Food and Drug Administration and identified 30 that have the
potential to address an unmet need, offer an improvement over
existing therapies and/or treat a serious condition. These 30
medicines were also analyzed for their potential budgetary impact.
Of the 30 new medicines selected, 20 were designated as orphan
drugs by the Food and Drug Administration (FDA) or the European
Medicines Agency (EMA) (including 8 gene therapies), 9 were
oncology medicines and 3 were biologics. Future editions of this
annual publication will monitor the pipeline list featured in this
report.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
